Market Highlights
The Rapid Influenza Diagnostics Tests Market is estimated to be valued at USD 954.512 million by 2023 and is expected to register a CAGR of 7.80% during the forecast period 2018-2023
Based on type of flu, the type A flu segment accounted for the largest market share in 2017, with a market value of USD 286.401 million. Influenza is a contagious respiratory infection caused by numerous flu viruses which affect the nose, throat, and lungs. As per the National Center for Biotechnology Information (NCBI) Report 2015, the influenza virus is responsible for seasonal epidemics affecting over 200,000 people with a death toll of approximately 30,000 to 50,000 patients every year in the US. As per the World Health Organization Report (WHO) 2017, influenza virus-infected 5% to 15% of the global population. As the prevalence of influenza is increasing, the number of diagnostic techniques such as immunochromatography-based rapid diagnostic test (RDT) and nucleic acid amplification test (NAAT) are used for the detection of influenza viruses in humans.
Segment Analysis
The global Rapid Influenza Diagnostics Tests Market is segmented into type of flu, test type, and end user. On the basis of type of flu, the global influenza diagnostics market is further sub-segmented as type A flu, type B flu, and type C flu. The type A flu accounted for the market value of USD 286.401 million in 2017.
By test type, the global influenza diagnostics market has been sub-segmented into traditional diagnostic tests and molecular diagnostic tests. The test type segment accounted for the larger market share in 2017. However, the type of flu segment is expected to exhibit higher CAGR during the forecast period. Based on end user, the global influenza diagnostics market has been sub-segmented into hospitals clinical laboratories and point-of-care testing.
Request Free Sample Copy at:
https://www.marketresearchfuture.com/sample_request/3142
Regional Analysis
Geographically, the global influenza diagnostics market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East Africa. As per MRFR analysis, The Americas accounted for the largest market share of 38.0% in 2017, with a market value of USD 236.198 million, the market is expected to register a CAGR of 7.25% during the forecast period. Europe was the second-largest market in 2017. However, the market in Asia-Pacific is expected to register the highest CAGR.
Key Findings of the Study:
- Global Rapid Influenza Diagnostics Tests Market is projected to reach over USD 954.512 million by 2023 with 7.80% CAGR during the review period of 2018 to 2023
- The Middle East and Africa holds the lowest share in the global influenza diagnostics market due to low development, lack of technical knowledge, and poor medical facilities.
- Based on type of flu the type A flu segment holds the largest market value of USD 286.401 million in 2017.
Some of the players operating in the global influenza diagnostics market are Abbott, Analytik Jena AG, Becton, Dickinson and Company, Biocartis, bioMérieux Inc, Cepheid, DiaSorin S.p.A., F. Hoffmann-La Roche Ltd, GenMark Diagnostics, Inc., Luminex Corporation, Meridian Bioscience, Inc., Quidel Corporation, SA Scientific, Thermo Fisher Scientific Inc.
Browse Detailed TOC with COVID-19 Impact Analysis at:
https://www.marketresearchfuture.com/reports/influenza-diagnostics-market-3142
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: sales@marketresearchfuture.com
